NEW YORK (AP) - Novartis AG said its leukemia drug candidate Tasigna received priority review by the Food and Drug Administration.

The special designation speeds up the regulatory review process to six months from the usual 10 months.

Novartis, based in Switzerland, also makes the cancer drug Gleevec.

Date: February 19, 2010
Source: Associated Press